| Prev Close | 193.09 |
| Day Low/High | 194.50 / 199.78 |
| 52 Wk Low/High | 187.16 / 468.55 |
Biogen Inc. (BIIB)
199.65
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 146.45B |
| Market Cap | 28.28B |
| P/E Ratio | 8.89 |
| Div & Yield | N.A. (N.A) |
Where to Buy in 2014: Part II
Here are four more themes where you can put money to work.
Time to Reconsider Sector Weights
Rather than follow the crowd, I want to lead it.
Big Pharma Emerges From the Wilderness
These four names are soaring, and I'd jump into all of them, even after their recent runs.
Cramer: The Top-Calling Finally Arrives
Apparently it's 'bad' now that the public has stopped pulling reams of money out of the market.
Watch the Charts on Biogen Idec
Timing cycles suggest reversal of BIIB's recent decline.
Searching for Pockets of Strength
The market is richly priced right now, but you can still find bargains.
Merck, Biogen Kick Off Fed Week
Biogen and Merck earnings emerge as investors wait for the Federal Reserve's latest policy-making statement.
Understanding the Highflying Stocks
When forces line up against them, they tend to fall hard.
Do Not Read This, Herb
It's best for Mr. Greenberg to avert his eyes.
Cramer: Anointed Stocks to Buy
Jim Cramer looks at the top performers of 2013 that should surge into the end of the year, with Mad Money Research Director Nicole Urken.
Off the Charts
Due to two non-economic factors, the Fed may not taper until 2014.
Off the Charts
Watch short-term pivots for effect of today's move.
Off the Charts
Pare down risk in some excess long positions.
Off the Charts
Use 1684 as your short-term point of reference and keep taking trades in light volume.
Pounce on the Anointed Ones
These stocks look bound to get bought at every dip through year-end. You should buy up, too -- but wait for that swoon.
Cramer: Celgene Is a Buy as Biotech Deals Heat-up
Jim Cramer looks at the latest biotech deals as Cubist acquires Trius amid changes among Biotech companies.
A Possible Secondary Entry in Biogen
If the rally does resume, I see a target around $255.
Early-Morning Market Look
Let's take a peek at the price action overnight and in the early morning in the more important asset classes. The rundown: S&P futures down 9 handles; Nikkei down 1.15%; European markets down -- a lot of earnings disappointments overnight, including...
Daily Recap of the Charts, July 19
John Darsie of T3Live review the day's market action and sets up your trading plan for the next session.
The Real Tech Boom Is Under Way
This sector offers the best growth opportunity over the next decade.
Analysis: SPY, USO, GS, BIIB & AWAY
Henry Gambell of Simpler Options steps in for John Carter noting levels we're looking to take profits on SPY and USO along with analysis on GS, BIIB & AWAY.
Playing the Biotechs
There have been some really good winners this year. By Bob Lang One of the best sectors to play this year has been the biotechs and I would be remiss if I didn't tell you my best play ever was just a couple weeks ago with Onyx Pharmaceutical (ONXX),...
Morning Call, June 27
Brittany Umar and Scott Redler, chief strategic officer at T3Live.com, reveal how to trade stocks ahead of earnings season: retail, banks, tech.
Off the Charts
Could snapback be the result of end-of-quarter window dressing?
Off the Charts
The S&P is currently in no-man's land.
